

## RESEARCH

# Initial clinical presentation and spectrum of pheochromocytoma: a study of 94 cases from a single center

Henrik Falhammar<sup>1,2</sup>, Magnus Kjellman<sup>2,3</sup> and Jan Calissendorff<sup>1,2</sup>

<sup>1</sup>Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm, Sweden

<sup>2</sup>Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden

<sup>3</sup>Department of Breast and Endocrine Surgery, Karolinska University Hospital, Stockholm, Sweden

Correspondence should be addressed to J Calissendorff: [jan.calissendorff@sl.se](mailto:jan.calissendorff@sl.se)

## Abstract

**Background:** With the increasing access to imaging more pheochromocytomas are diagnosed in the workup of adrenal incidentalomas. This may have changed the occurrence of the classic presentation with hypertension and the classic triad (headaches, sweating and palpitation).

**Methods:** We reviewed 94 consecutive cases of pheochromocytomas. Two cases of ectopic ACTH-syndrome were subsequently excluded.

**Results:** Of the 92 cases included 64% had presented as an incidentaloma, 32% as a suspected pheochromocytoma and 4% had been screened because of previously diagnosed MEN2A. Those screened were youngest while those with incidentalomas were oldest. The females were more common in the incidentaloma and the screening groups, and males in the suspected pheochromocytoma group. Measurements of noradrenaline/normetanephrine levels were highest in the suspected pheochromocytoma group and lowest in the screening group. Hypertension was present in 63% of the incidentalomas, 79% of suspected pheochromocytomas and in none of the screening group. Paroxysmal symptoms were present in almost all with suspected pheochromocytoma while only in half of the other groups. The suspected pheochromocytoma group had most symptoms and the screening group least. The classic triad was present in 14% of the incidentalomas, in 28% of the suspected and in none of the screening group, while no symptoms at all was present in 12%, 0% and 25%, respectively. Pheochromocytoma crisis occurred in 5%. There was a positive correlation between tumor size vs hormone levels, and catecholamine levels vs blood pressure.

**Conclusion:** Clinicians need to be aware of the modern presentation of pheochromocytomas since early identification can be life-saving.

## Key Words

- ▶ pheochromocytoma
- ▶ symptoms
- ▶ adrenal incidentaloma
- ▶ blood pressure
- ▶ cardiovascular disease
- ▶ diabetes

*Endocrine Connections*  
(2018) 7, 186–192

## Introduction

Pheochromocytomas are neuroendocrine tumors arising from chromaffin cells of the adrenal medulla or in extra-adrenal paraganglia producing catecholamines. Tumors outside the adrenals are usually called extra-adrenal pheochromocytomas or paragangliomas and only

represent around 15–20% of all catecholamine-secreting tumors (1). Pheochromocytomas are rare but in certain groups such as in patients with adrenal incidentalomas 0.6–4.2% are affected (2, 3, 4). Pheochromocytoma is a serious condition which can be fatal if not diagnosed

and/or managed appropriately (1, 5). It has been estimated that at least 25% of all affected by pheochromocytomas were never diagnosed during life (6).

The presenting symptoms of pheochromocytomas can vary to a large extent and similar symptoms can occur in many other clinical conditions. Thus, it is often called the great mimic and there can be a significant delay of diagnosis (7). Most cases have previously been found due to symptoms suspected to be related to catecholamine excess, typically paroxysmal hypertension and the classic triad of headaches, sweating and palpitation. However, with the increasing use of high resolution imaging techniques in the past decades more incidentalomas have been detected. It has also been reported that more of all pheochromocytomas were discovered in the workup for incidentalomas (7), but this study only included patients up to 2003. It can be assumed that this development has continued during the last 15 years. Moreover, individuals are also nowadays found in the family screening for genetic syndromes that are associated with catecholamine producing tumors (e.g. multiple endocrine neoplasia type 2, Von Hippel Lindau syndrome, neurofibromatosis type 1, and mutations in succinate dehydrogenase B, C and D). Thus, the clinical presentation has most likely changed over time and may not be as perceived previously.

The aims of the present study were to determine in a large modern cohort of pheochromocytomas the presenting characteristics and investigate differences in presentation in those presenting as incidentalomas, those with symptoms suspected to be pheochromocytoma and those found in the screening since they had been diagnosed with a familial syndrome.

## Subjects and methods

This retrospective study was conducted at the Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm, Sweden. All consecutive patients with an International Classification of Diseases version 10 (ICD-10) code of E27.5 (adrenomedullary hyperfunction) and/or C74.1 (malignant neoplasm of medulla of adrenal gland) and had been admitted and/or attended the out-patient clinic between June 2005 and June 2016 were eligible for inclusion. The patients' electronic medical files were reviewed manually and those where a pheochromocytoma could not be confirmed were subsequently excluded. The National Population Register was also consulted to find out if the patient was still alive and the date of death was retrieved if applicable

(8). In Sweden, all hospital admissions and specialist out-patient visits are coded with ICD-10 codes by the attending physician and stored in local and national databases (9). Presenting symptoms, co-morbidities, blood pressure, biochemistry, imaging and tumor size recorded in the files were noted. Patients with relapse of their pheochromocytoma were included only for the first episode.

High-performance liquid chromatography (HPLC) was used for determinations of 24h urinary adrenaline and noradrenaline (normal <80 and <400 nmol/24h, respectively), and liquid chromatography–tandem mass spectrometry (LC/MS/MS) for plasma metanephrine and normetanephrine (normal <0.3 and <0.6 nmol/L, respectively). Plasma chromogranin A was measured using enzyme-linked immunosorbent assay (ELISA) (normal <3.0 nmol/L).

The Regional Ethical Review Board in Stockholm, Sweden, approved the study. For this type of retrospective study formal consent was not required.

## Statistical analysis

Mean  $\pm$  s.d. or median and range were used whichever were appropriate. Continuous variables were between two groups compared with unpaired *t*-test when values (normally distributed) or Mann–Whitney rank-sum test, and between three groups with one-way ANOVA (normal distributions) with *post hoc* Holm–Sidak test or with ANOVA on ranks test and *post hoc* Dunn's test. In frequency table calculations, chi-square or Fisher's exact test was used whichever was appropriate. All proportions were calculated discounting missing values. Correlations between variables were assessed using linear regression analysis. Statistical significance was set at  $P < 0.05$ . SigmaStat 3.0 for Windows (Systat Software, San Jose, California) was used for all analysis.

## Results

In total, 94 cases of pheochromocytomas were identified. However, two cases (one with adrenal medullary hyperplasia) had also given rise to an ectopic ACTH syndrome and were subsequently excluded from further analysis since they represent a somewhat different entity, and they have been described in detail previously (10). We were also aware of two adrenocortical cancers with concomitant catecholamine excess, but they had not been given an eligible ICD code (E27.5 or C74.1), and

their presentations were of an ACC (11), so they were not included either. Thus, 92 cases were included in the analysis of which 59 (64%) presented as an incidentaloma and 29 (32%) as a suspected pheochromocytoma, while 4 (4%) were found in the regular catecholamine screening performed due to a previously diagnosed familial syndrome. All patients except three (3%, all in the incidentaloma group) had adrenalectomy and the diagnosis was confirmed histologically. Of these three individuals, one declined surgery due to old age, one due to extensive separate adenocarcinoma and one deceased prior to surgery due to severe heart failure and severe amyloidosis due to multiple myeloma; the biochemistry results and imaging clearly indicated pheochromocytoma in all, and the response to alfa blockage was excellent. A CT scan had been done in 91 cases (99%), one had only a MRI. In all 14 had been investigated with MRI (incidentaloma group  $n=8$  and suspected pheochromocytoma  $n=6$ , all showing typical features). In addition,  $^{123}\text{I}$ -metaiodobenzylguanidine (MIBG) scans had been done in 32 patients (incidentaloma group  $n=19$ ,

suspected pheochromocytoma group  $n=11$  and screening group  $n=2$ , respectively) with 28 (88%) showing a clear uptake in the tumor (incidentaloma group  $n=17$  (89%), suspected pheochromocytoma group  $n=10$  (91%) and screening group  $n=1$  (50%), respectively,  $P=0.252$ ). PET was done in four patients (incidentaloma group  $n=3$  and screening group  $n=1$ ) of which three were with  $^{11}\text{C}$ -hydroxyephedrine and one with  $^{18}\text{F}$ -fludeoxyglucose (incidentaloma), all showing an uptake in the pheochromocytoma. Four patients with incidentaloma (7%, follow-up time  $7.5\pm 3.9$  years) died compared to five patients with suspected pheochromocytoma (17%,  $11.7\pm 8.7$  years) and none of the patients screened (0%,  $7.5\pm 3.9$  years) ( $P=0.239$ ).

### All included patients with a pheochromocytoma

The mean age at diagnosis was  $56.3\pm 16.1$  years (range 19–85), and the tumor size was  $49\pm 26.7$  mm (range 8–125) (Table 1). The urine adrenaline and/or plasma metanephrine were almost three times the upper level

**Table 1** Presenting characteristics of adult patients with pheochromocytomas, also divided into how they presented.

	All ( $n=92$ )	Incidentaloma presentation ( $n=59$ )	Pheo suspicion ( $n=29$ )	P value	Screening ( $n=4$ )	P value between all three groups
Age at diagnosis (years)	$56.3\pm 16.1$	$59.7\pm 14.1$	$52.4\pm 17.6$	<b>0.037</b>	$33.3\pm 8.7$	<b>0.001*</b>
Females ( $n$ )	47 (51%)	35 (59%)	9 (31%)	<b>0.023</b>	3 (75%)	<b>0.028</b>
Tumor size (mm)	$49.0\pm 26.7$	$49.2\pm 24.1$	$51.8\pm 32.2$	0.675	$26.3\pm 12.5$	0.141
Right-sided tumor ( $n$ )	50 (54%)	32 (54%)	16 (55%)	0.885	2 (50%)	0.981
Bilateral ( $n$ )	1 (1%)	0 (0%)	1 (3%)	0.330	0 (0%)	0.333
U-adrenaline (nmol/24 h)	119 (10–8000)	87 (10–8000)	140 (56–584)	0.321	225 (159–291)	0.452
U-noradrenaline (nmol/24 h)	858 (161–34300)	717 (161–10700)	1500 (446–8158)	<b>0.003</b>	536 (247–825)	<b>0.010**</b>
P-metanephrine (nmol/L)	0.8 (0.2–190)	0.8 (0.2–12)	2.0 (0.3–7.4)	0.051	0.8 (0.7–1.4)	0.130
P-normetanephrine (nmol/L)	5.2 (0.7–160)	5.0 (0.7–61)	15.5 (2.0–47.0)	<b>&lt;0.001</b>	0.9 (0.7–1.3)	<b>0.011*</b>
U-A/P-MNE	2.7 (0.3–633)	2.3 (0.3–100)	3.6 (0.3–633)	0.451	3.2 (2.3–4.7)	0.721
U-NA/P-NMNE	6.0 (0.2–267)	7.3 (0.8–102)	7.3 (0.7–267)	<b>0.007</b>	1.8 (0.2–2.2)	<b>0.030**</b>
Highest hormone ratio	11.0 (1.2–633)	11.0 (1.2–102)	16.3 (1.3–633)	<b>0.014</b>	3.2 (3.2–4.7)	<b>0.025*</b>
P-CGA (nmol/L)	10.5 (2.4–367)	11.0 (2.4–170)	8.9 (4.5–367)	0.918	3.3 (2.4–4.2)	0.100
SBP (mmHg)	$155\pm 30$	$151\pm 25$	$167\pm 37$	<b>0.021</b>	$126\pm 15$	<b>0.010*</b>
DBP (mmHg)	$88\pm 14$	$87\pm 12$	$92\pm 18$	0.135	$75\pm 7$	0.051
Sustained HT ( $n$ )	60 (67%)	37 (63%)	23 (79%)	0.147	0 (0%)	<b>0.006</b>
Only paroxysmal HT ( $n$ )	7 (8%)	3 (5%)	4 (14%)	0.212	0 (0%)	0.295
Always normotensive ( $n$ )	25 (27%)	19 (32%)	2 (7%)	<b>0.008</b>	4 (100%)	<b>&lt;0.001</b>
Type 2 diabetes ( $n$ )	25 (27%)	13 (22%)	12 (41%)	0.079	0 (0%)	0.073
Pre-diabetes <sup>§</sup> ( $n$ )	16 (17%)	13 (22%)	2 (7%)	0.129	1 (25%)	0.195
Glucose abnormality ( $n$ )	41 (45%)	26 (44%)	14 (48%)	0.821	1 (25%)	0.675
Cardiovascular disease ( $n$ )	33 (36%)	20 (34%)	13 (45%)	0.355	0 (0%)	0.187

Pheo, pheochromocytoma. All patients screened due to familial syndrome had a previously known *RET* mutation (MEN2A). U, urinary; P, plasma. U-A/P-MNE, highest U-adrenaline or P-metanephrine level divided the upper level of normal. U-NA/P-NMNE, highest U-noradrenaline or P-normetanephrine level divided the upper level of normal. P-CGA, P-chromogranin A. Reference ranges were for urinary adrenaline and noradrenaline <80 and <400 nmol/24 h, respectively, for plasma metanephrine and normetanephrine <0.3 and <0.6 nmol/L, respectively, and for plasma chromogranin A normal <3.0 nmol/L. SBP, systolic blood pressure. DBP, diastolic blood pressure. Blood pressure before specific treatment for pheochromocytoma such as alfa-blocker. HT, hypertension. *P* value between the different presentation groups. Bold,  $P<0.05$ . *P* value after *post hoc* Holm–Sidak or Dunn’s test: \*Significant between all 3 groups; \*\*Significant between incidentaloma presentation and Pheo suspicion groups. <sup>§</sup>Defined as fasting plasma glucose 6–6.9 mmol/L and/or a 2 h OGTT value 7.8–11 and/or a HbA1c 42–47 mmol/mol.

of normal, the urine noradrenaline and/or plasma normetanephrine were six times the upper level of normal and if only the highest level was accounted for in each case, the level was 11 times the upper level of normal. Plasma chromogranin A was also elevated. On average, the blood pressure was moderately elevated and two thirds had hypertension. Almost half had some glucose abnormality and a third cardiovascular disease. Paroxysmal symptoms were present in 62% (Table 2). The most common symptoms with more than a third affected were in falling order: palpitations, anxiety, sweating and headaches. The median number of different symptoms was three and almost a tenth was asymptomatic. The classic triad with headaches, sweating and palpitation was only present in 17%. Five patients (5%), mean age 51.5±23.5 years (range 27–76 years), were diagnosed in conjunction with a pheochromocytoma crisis with multi-organ failure triggered by surgery (*n*=2, coronary bypass and uvulopalatopharyngoplasty, respectively), vaginal delivery (*n*=1), influenza (*n*=1) and unknown cause (*n*=1). None had metastatic disease at presentation; however, two later developed metastasis (both in the suspected pheochromocytoma group).

### Presentation as an adrenal incidentaloma, suspected pheochromocytoma or screening

The majority (*n*=59, 64%) had been found in the workup of an incidentaloma (all had had a CT scan), i.e., there had not been any suspicions of a pheochromocytoma before imaging. The reasons for imaging were abdominal

pain/discomfort (*n*=36, 61%), hematuria/urine tract issues (*n*=10, 17%), thoracic pain/investigation (*n*=12, 20%) and multi-trauma (*n*=1, 2%). In about a third (*n*=29, 32%), the pheochromocytoma had been suspected and investigations to confirm or rule it out had been ordered. In a small group (*n*=4, 4%), biochemical screening for pheochromocytoma had been performed at regular intervals due to familial syndrome with an increased risk of developing a pheochromocytoma. In the incidentaloma group, only in 11 (19%), a gene test result was found (27% positive, *n*=3) and in suspected pheochromocytoma group, six (21%) (17% positive, *n*=1) but all screened patients had known *RET*-mutation confirming MEN2A (100% positive, *n*=4). When the three groups were compared some differences were found. Those screened were the youngest while those with incidentalomas were the oldest (Table 1). The predominant gender was females in the incidentaloma and the screening groups and males in the suspected pheochromocytoma group. Measurements of noradrenaline/normetanephrine levels were highest in the suspected pheochromocytoma group and lowest in the screening group. There were no differences in adrenaline/metanephrine levels between the groups. The highest hormone ratio was in the suspected and lowest in the screening group. Systolic blood pressure was highest in the suspected group and lowest in the screening group. Constant hypertension was present in 63% in the incidentaloma, 79% in the suspected pheochromocytoma but in none of the screening group, while only paroxysmal hypertension was present in 5%, 14% and 0%, respectively. There was a tendency to be

**Table 2** Presenting symptoms of adult patients with pheochromocytomas, also divided into how they presented.

	All ( <i>n</i> =92)	Incidentaloma presentation ( <i>n</i> =59)	Pheo suspicion ( <i>n</i> =29)	<i>P</i> value incidentaloma vs Pheo suspicion	Screening ( <i>n</i> =4)	<i>P</i> value between all three groups
Paroxysmal symptoms ( <i>n</i> )	57 (62%)	29 (49%)	26 (90%)	<0.001	2 (50%)	0.001
Headaches ( <i>n</i> )	34 (37%)	17 (29%)	16 (55%)	0.020	1 (25%)	0.048
Palpitation ( <i>n</i> )	49 (53%)	26 (44%)	22 (76%)	0.006	1 (25%)	0.010
Sweating ( <i>n</i> )	38 (41%)	23 (39%)	15 (52%)	0.360	0 (0%)	0.120
Pallor ( <i>n</i> )	11 (12%)	3 (5%)	7 (24%)	0.013	1 (25%)	0.025
Anxiety ( <i>n</i> )	42 (46%)	26 (44%)	13 (45%)	0.872	3 (75%)	0.483
Feeling hot/flush ( <i>n</i> )	22 (24%)	13 (22%)	9 (31%)	0.434	0 (0%)	0.336
Nausea ( <i>n</i> )	20 (22%)	8 (14%)	12 (41%)	0.006	0 (0%)	0.007
Weight loss ( <i>n</i> )	15 (16%)	11 (19%)	4 (14%)	0.765	0 (0%)	0.563
Tiredness ( <i>n</i> )	26 (28%)	18 (31%)	8 (28%)	0.973	0 (0%)	0.421
Tremor ( <i>n</i> )	13 (14%)	4 (7%)	8 (28%)	0.017	1 (25%)	0.025
Orthostatic symptoms ( <i>n</i> )	25 (27%)	11 (19%)	13 (45%)	0.019	1 (25%)	0.034
No symptoms at all ( <i>n</i> )	8 (9%)	7 (12%)	0 (0%)	0.090	1 (25%)	0.089
Different symptoms ( <i>n</i> )	3 (0–10)	3 (0–10)	4 (2–8)	<0.001	1 (0–6)	0.001
Classic triad ( <i>n</i> )	16 (17%)	8 (14%)	8 (28%)	0.143	0 (0%)	0.170

Pheo, pheochromocytoma. All patients screened due to familial syndrome had a previously known *RET* mutation (MEN2A). Bold, *P*<0.05. The classic triad with paroxysmal symptoms was defined as headaches, sweating and palpitation.

**Table 3** Correlations in adult patients with pheochromocytomas with different presenting characteristics.

	All (n=92)	Incidentaloma presentation (n=59)	Pheo suspicion (n=29)	Screening (n=4)
Tumor size vs U-A/P-MNE	NS	NS	NS	NS
Tumor size vs U-NA/P-NMNE	$R=0.37, P<0.001$	$R=0.41, P=0.002$	$R=0.42, P=0.027$	NS
Tumor size vs hormone levels	NS	$R=0.30, P=0.027$	NS	NS
Tumor size vs P-CGA	$R=0.39, P=0.006$	NS	$R=0.78, P=0.005$	NS
Tumor size vs SBP	NS	NS	NS	NS
Tumor size vs DBP	NS	NS	NS	NS
Tumor size vs symptoms	NS	NS	$R=0.33, P=0.049$	NS
Tumor size vs age	NS	NS	NS	NS
U-A/P-MNE vs SBP	$R=0.39, P<0.001$	NS	$R=0.52, P=0.006$	NS
U-A/P-MNE vs DBP	$R=0.60, P<0.001$	NS	$R=0.37, P=0.043$	NS
U-A/P-MNE vs symptoms	NS	NS	NS	NS
U-A/P-MNE vs age	NS	NS	NS	NS
U-NA/P-NMNE vs SBP	$R=0.33, P=0.002$	NS	$R=0.36, P=0.042$	NS
U-NA/P-NMNE vs DBP	$R=0.34, P=0.001$	NS	$R=0.391, P=0.44$	NS
U-NA/P-NMNE vs symptoms	NS	$R=0.43, P<0.001$	$R=0.33, P=0.048$	NS
U-NA/P-NMNE vs age	NS	NS	NS	NS
Hormone levels vs SBP	$R=0.41, P<0.001$	NS	$R=0.51, P=0.006$	NS
Hormone levels vs DBP	$R=0.36, P<0.001$	NS	$R=0.43, P=0.024$	NS
Hormone levels vs symptoms	NS	$R=0.38, P=0.003$	NS	NS
Hormone levels vs age	NS	NS	NS	NS
Age vs symptoms	$R=-0.19, P=0.046$	NS	NS	NS

Pheo, pheochromocytoma. All patients screened due to familial syndrome had a previously known *RET* mutation (MEN2A). U-A/P-MNE, highest U-adrenaline or P-metanephrine level divided by the upper level of normal. U-NA/P-NMNE, highest U-noradrenaline or P-normetanephrine level divided by the upper level of normal. Hormone levels were defined as the highest catecholamine levels divided by the upper level of normal. P-CGA, P-chromogranin A. SBP, systolic blood pressure. DBP, diastolic blood pressure. Symptoms were defined as number of symptoms at presentation. NS, non-significant.

more type 2 diabetes in the suspected pheochromocytoma group. Paroxysmal symptoms were present in almost all with suspected pheochromocytoma while only half of the other groups had these (Table 2). The symptoms that differed significantly between the groups were headaches, palpitations, pallor, nausea, tremor and orthostatic symptoms. The suspected pheochromocytoma group had most different symptoms and the screening group least.

### Correlations between different presenting characteristics

In all patients, there was a positive correlation between tumor size vs noradrenaline/normetanephrine levels and chromogranin A, catecholamine levels vs blood pressure and a negative correlation between age vs number of symptoms (Table 3). In the different subgroups, there were most different correlations in the pheochromocytoma suspicion group and some in the AI presentation group.

### Discussion

This large modern study confirms the wide spectrum of presentations of pheochromocytomas but also that

hypertension and typical symptoms may not be present at all. The predominant presentation was serendipitously in the workup of an incidentaloma. Even though the patients with incidentalomas had not sought medical attention for pheochromocytoma-related symptoms, in hindsight, 88% had symptoms, which could be related to this disorder. Those screened had very few symptoms while those found in the workup of suspected pheochromocytoma had most symptoms. The classic triad, i.e., headaches, sweating and palpitation, was only present in a minority of patients.

Amar and coworkers reported in their study that 15% presented as an incidentaloma. However, their study spanned from 1975 to 2003 and if only those 48 diagnosed during the last quartile of this period were considered, 25% presented as an incidentaloma (7). Also other studies, spanning from 1973 to 2011 have found <10%–41% of patients with pheochromocytoma in the course of imaging for something unrelated (12, 13, 14, 15). Thus, the presentation as an incidentaloma was much higher in our study (64%); however, we included patients up to 2016 and the increased use of imaging techniques could probably explain the difference. The high proportion of incidentalomas in our study was probably the main reasons why the rate of bilateral tumors was so low. In accordance with this, the rate of bilateral pheochromocytomas

decreased in the investigation by Amar and coworkers over time (7). Moreover, our study only investigated the initial presentation and a pheochromocytoma may be found in the other adrenal during long-time follow-up increasing the rate of bilateral tumors. It can be assumed that this presentation will continue to increase in the future with even easier access to radiology. Even though a catecholamine-secreting tumor was not suspected in these cases, in hindsight, these were not silent tumors. Around half had paroxysmal symptoms, two-thirds had hypertension, glucose abnormalities were present in almost half and a third had cardiovascular disease. This demonstrates the difficulties in suspecting this potentially lethal condition.

Even though the characteristics in pheochromocytomas presenting as incidentaloma, suspected pheochromocytoma and in screening have been compared previously (12), this is the largest and most detailed study including all the different symptoms so far. We found correlations with different presenting characteristics, even in the subgroups. For example, we demonstrated a relationship between tumor size and hormone level in the entire group, in the incidentaloma and the suspected pheochromocytoma groups, which has previously only been reported once (12). We also found correlations between catecholamine levels and blood pressure in the entire and pheochromocytoma suspicion groups and associations between catecholamine levels and the number of symptoms, however, not that consistent, which have not been reported previously.

Unfortunately, the screening group in the present study consisted of only four individuals; however, the result did not differ much if only the two larger groups were compared. Generally, those suspected of having a pheochromocytoma were males, had higher noradrenaline/normetanephrine levels, higher blood pressure, more general and paroxysmal symptoms and were more affected by type 2 diabetes and cardiovascular disease (the latter two were not significant), while those with a familial syndrome were females (3/4) and had very little symptoms and signs since they were found very early, thanks to regular screening. Those screened had smaller tumors, in accordance with others (12), but this did not reach a significant level in our study. Those with incidentalomas were older than the other groups. It is worth noting that 25% of those with familial syndrome did not have any symptoms in spite of a catecholamine-secreting tumor being known and symptoms were actively sought after. In the incidentaloma group, no symptoms were found in 12%. Thus, most patients

had symptoms but these had not been identified to be related to a pheochromocytoma before the biochemical results came back. In the entire cohort, 9% did not have any symptoms at all which is similar to others (7, 13). Sustained hypertension was present in 63% of those with an incidentaloma, in 80% of those suspected of having a pheochromocytoma and in none of those screened. A quarter off all, a third of the incidentaloma group, less than a tenth of the suspected pheochromocytoma group and all in the screening group did not even have paroxysmal hypertension, which seems lower incidence than in some (7, 13), but not all publications (14). However, we may have missed some with paroxysmal hypertension. Thus, normal blood pressure cannot exclude a pheochromocytoma. A large proportion, except in the screening group, had had a cardiovascular event before being diagnosed with pheochromocytoma. It could be suspected that the increased catecholamine secretion had contributed to this event in most cases, and one could wonder how many fatal cardiovascular events associated with pheochromocytomas have occurred without being diagnosed (16). Five of our cases presented with a pheochromocytoma crisis with multi-organ failure, which is a life-threatening event needing prompt recognition, initial stabilization and sufficient  $\alpha$ -blockage prior to surgery (15). Laparoscopic transperitoneal adrenalectomy is considered the 'gold standard', at least for tumors <6 cm, but adrenalectomy by a minimally invasive retroperitoneal approach is increasing in popularity (17). Our frequency of 5% crisis is lower than the 11% reported from a multi-center German study; however, they included all being admitted to ICU due to a pheochromocytoma-related complication, but only 3% had, similar to our results, multi-organ failure (7).

Even though most patients did not have a suspicion of a pheochromocytoma initially, after being diagnosed, the frequency of different symptoms in the incidentaloma and suspected pheochromocytoma groups were fairly similar to what others have reported in the last decade (13). Even though the classical triad has been reported to have a specificity and sensitivity of more than 90% (18), only 17% had the classic triad in the present study (28% in those with suspected pheochromocytoma), which is similar to others (14). Thus, nowadays pheochromocytomas do not frequently present with the classic triad.

The inherent limitations of all retrospective studies, in particular that of ascertainment bias, were also present in this study. Even though the study was large comparing to similar single-center studies, the screening group only included four individuals. Moreover, we were not able to

standardize the measurements of hormonal and genetic tests due to the retrospective nature of the study.

In conclusion, the clinical presentation of pheochromocytomas can be anything from asymptomatic to a dramatic life-threatening event. This rare condition is important to bear in mind in the workup of patients with incidentalomas, which nowadays were the most common presentation of pheochromocytomas due to the better availability and accessibility of imaging procedures. In hindsight, most of these were not asymptomatic, but due to the diffuse symptoms, catecholamine-secreting tumors were not considered. A normal blood pressure did not exclude a pheochromocytoma. Clinicians need to be aware of the clinical presentation of pheochromocytomas today since their early identification can be life-saving.

#### Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

#### Funding

This was an academic investigation with funding from the Magnus Bergvall Foundation. This study was supported by Karolinska Institutet and the Stockholm County Council.

## References

- 1 Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, Naruse M, Pacak K, Young WF Jr & Endocrine S. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. *Journal of Clinical Endocrinology and Metabolism* 2014 **99** 1915–1942.
- 2 Yeomans H, Calissendorff J, Volpe C, Falhammar H & Mannheimer B. Limited value of long-term biochemical follow-up in patients with adrenal incidentalomas—a retrospective cohort study. *BMC Endocrine Disorders* 2015 **15** 6. (<https://doi.org/10.1186/s12902-015-0001-x>)
- 3 Patrova J, Jarocka I, Wahrenberg H & Falhammar H. Clinical outcomes in adrenal incidentaloma: experience from one center. *Endocrine Practice* 2015 **21** 870–877. (<https://doi.org/10.4158/EP15618.OR>)
- 4 Mantero F, Terzolo M, Arnaldi G, Osella G, Masini AM, Ali A, Giovagnetti M, Opocher G & Angeli A. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. *Journal of Clinical Endocrinology and Metabolism* 2000 **85** 637–644.
- 5 Rieder A, Weismann D, Quinkler M, Lichtenauer UD, Sommerer S, Halbritter R, Penning R, Spitzweg C, Schopohl J, Beuschlein F, *et al.* Life-threatening events in patients with pheochromocytoma. *European Journal of Endocrinology* 2015 **173** 757–764. (<https://doi.org/10.1530/EJE-15-0483>)
- 6 Khorram-Manesh A, Ahlman H, Nilsson O, Oden A & Jansson S. Mortality associated with pheochromocytoma in a large Swedish cohort. *European Journal of Surgical Oncology* 2004 **30** 556–559. (<https://doi.org/10.1016/j.ejso.2004.03.006>)
- 7 Amar L, Servais A, Gimenez-Roqueplo AP, Zinzindohoue F, Chatellier G & Plouin PF. Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. *Journal of Clinical Endocrinology and Metabolism* 2005 **90** 2110–2116. (<https://doi.org/10.1210/jc.2004-1398>)
- 8 Patrova J, Kjellman M, Wahrenberg H & Falhammar H. Increased mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: a 13-year retrospective study from one center. *Endocrine* 2017 **58** 267–275. (<https://doi.org/10.1007/s12020-017-1400-8>)
- 9 Falhammar H, Frisen L, Hirschberg AL, Norrby C, Almqvist C, Nordenskjold A & Nordenstrom A. Increased cardiovascular and metabolic morbidity in patients with 21-hydroxylase deficiency: a Swedish population-based national cohort study. *Journal of Clinical Endocrinology and Metabolism* 2015 **100** 3520–3528. (<https://doi.org/10.1210/JC.2015-2093>)
- 10 Falhammar H, Calissendorff J & Hoybye C. Frequency of Cushing's syndrome due to ACTH-secreting adrenal medullary lesions: a retrospective study over 10 years from a single center. *Endocrine* 2017 **55** 296–302. (<https://doi.org/10.1007/s12020-016-1127-y>)
- 11 Calissendorff J, Calissendorff F & Falhammar H. Adrenocortical cancer: mortality, hormone secretion, proliferation and urine steroids – experience from a single centre spanning three decades. *BMC Endocrine Disorders* 2016 **16** 15. (<https://doi.org/10.1186/s12902-016-0095-9>)
- 12 Guerrero MA, Schreinemakers JM, Vriens MR, Suh I, Hwang J, Shen WT, Gosnell J, Clark OH & Duh QY. Clinical spectrum of pheochromocytoma. *Journal of the American College of Surgeons* 2009 **209** 727–732. (<https://doi.org/10.1016/j.jamcollsurg.2009.09.022>)
- 13 Kopetschke R, Slisko M, Kilisli A, Tuschy U, Wallaschofski H, Fassnacht M, Ventz M, Beuschlein F, Reincke M, Reisch N, *et al.* Frequent incidental discovery of pheochromocytoma: data from a German cohort of 201 pheochromocytoma. *European Journal of Endocrinology* 2009 **161** 355–361. (<https://doi.org/10.1530/EJE-09-0384>)
- 14 Baguet JP, Hammer L, Mazzucco TL, Chabre O, Mallion JM, Sturm N & Chaffanjon P. Circumstances of discovery of pheochromocytoma: a retrospective study of 41 consecutive patients. *European Journal of Endocrinology* 2004 **150** 681–686. (<https://doi.org/10.1530/eje.0.1500681>)
- 15 Scholten A, Cisco RM, Vriens MR, Cohen JK, Mitmaker EJ, Liu C, Tyrrell JB, Shen WT & Duh QY. Pheochromocytoma crisis is not a surgical emergency. *Journal of Clinical Endocrinology and Metabolism* 2013 **98** 581–591. (<https://doi.org/10.1210/jc.2012-3020>)
- 16 Gu YW, Poste J, Kunal M, Schwarcz M & Weiss I. Cardiovascular manifestations of pheochromocytoma. *Cardiology in Review* 2017 **25** 215–222. (<https://doi.org/10.1097/CRD.0000000000000141>)
- 17 Conzo G, Tartaglia E, Gambardella C, Esposito D, Sciascia V, Mauriello C, Nunziata A, Siciliano G, Izzo G, Cavallo F, *et al.* Minimally invasive approach for adrenal lesions: systematic review of laparoscopic versus retroperitoneoscopic adrenalectomy and assessment of risk factors for complications. *International Journal of Surgery* 2016 **28** (Supplement 1) S118–S123. (<https://doi.org/10.1016/j.ijssu.2015.12.042>)
- 18 Plouin PF, Degoulet P, Tugay A, Ducrocq MB & Menard J. Screening for pheochromocytoma: in which hypertensive patients? A semiological study of 2585 patients, including 11 with pheochromocytoma (author's transl). *La Nouvelle Presse Medicale* 1981 **10** 869–872.

Received in final form 29 November 2017

Accepted 7 December 2017

Accepted Preprint published online 7 December 2017

